iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) saw some unusual options trading on Wednesday. Traders purchased 4,787 put options on the company. This represents an increase of approximately 60% compared to the typical volume of 2,993 put options.
Institutional Investors Weigh In On iShares Biotechnology ETF
Institutional investors and hedge funds have recently bought and sold shares of the company. Independence Bank of Kentucky raised its position in iShares Biotechnology ETF by 121.1% during the 2nd quarter. Independence Bank of Kentucky now owns 210 shares of the financial services provider’s stock valued at $25,000 after purchasing an additional 115 shares in the last quarter. Steward Financial Group LLC bought a new position in shares of iShares Biotechnology ETF in the 4th quarter worth $34,000. Close Asset Management Ltd bought a new position in shares of iShares Biotechnology ETF in the 2nd quarter worth $27,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in shares of iShares Biotechnology ETF in the 4th quarter worth $38,000. Finally, Horan Securities Inc. bought a new position in shares of iShares Biotechnology ETF in the 4th quarter worth $42,000. 63.88% of the stock is owned by institutional investors.
iShares Biotechnology ETF Stock Performance
IBB opened at $130.18 on Friday. The business has a fifty day moving average of $119.04 and a 200 day moving average of $123.00. iShares Biotechnology ETF has a 52-week low of $104.29 and a 52-week high of $177.37.
iShares Biotechnology ETF Cuts Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 15th. Investors of record on Friday, June 10th were issued a dividend of $0.031 per share. This represents a $0.12 dividend on an annualized basis and a yield of 0.10%. The ex-dividend date of this dividend was Thursday, June 9th.
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Receive News & Ratings for iShares Biotechnology ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iShares Biotechnology ETF and related companies with MarketBeat.com’s FREE daily email newsletter.